Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study

• Published in: Biomedicines 2022-01, Vol.10 (1), p.193
• Main Authors: Metzner, Thomas, Leitner, Deborah R, Mellitzer, Karin, Beck, Andrea, Sourij, Harald, Stojakovic, Tatjana, Reishofer, Gernot, März, Winfried, Landmesser, Ulf, Scharnagl, Hubert, Toplak, Hermann, Silbernagel, Günther
• Format: Article
• Language: English
• Subjects: alirocumab; Antibodies; Apolipoproteins; Arteriosclerosis; Cardiovascular disease; Cholesterol; COVID-19; Endothelium; Enzymes; Fat metabolism; fat-tolerance test; High density lipoprotein; Immunological tolerance; Laboratories; Lipase; Lipid metabolism; Lipids; Lipoproteins; Low density lipoprotein; Magnetic resonance spectroscopy; Metabolism; NMR; Nuclear magnetic resonance; nuclear magnetic resonance spectroscopy; Patients; PCSK9; Plasma; Proteins; Reagents; Spectrum analysis; Statins; Triglycerides; Vascular diseases
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10010193

PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators. A total of 24 patients with an indication for treatment with PCSK9 antibodies were recruited. There were two visits at the study site: the first before initiation of treatment with alirocumab and the second after 10 weeks of treatment. Fat-tolerance tests, nuclear magnetic resonance spectroscopy, and enzyme-linked immunosorbent assays were performed to analyze lipid metabolism. A total of 21 participants underwent the first and second investigation. Among these, two participants only received alirocumab twice and 19 patients completed the trial per protocol. All of them had atherosclerotic vascular disease. There was no significant effect of alirocumab treatment on fasting triglycerides, post-prandial triglycerides, or lipoprotein-lipase regulating proteins. Total, large, and small LDL particle concentrations decreased, while the HDL particle concentration increased (all < 0.001). Mean total circulating PCSK9 markedly increased in response to alirocumab treatment ( < 0.001). Whereas PCSK9 increased more than three-fold in all 19 compliant patients, it remained unchanged in those two patients with two injections only. Significant effects of alirocumab on triglyceride metabolism were not detectable in the ALIROCKS trial. The total circulating PCSK9 concentration might be a useful biomarker to differentiate non-adherence from non-response to PCSK9 antibodies.